ArticleEndocrine connections2026
Clinical and genetic spectrum of cytochrome P450 oxidoreductase deficiency in Chinese patients.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytochrome P450 oxidoreductase deficiency (PORD) is a rare autosomal recessive disorder with heterogeneous endocrine, reproductive, DSD-related, and skeletal manifestations. Population-specific data in Chinese patients remain limited.
methodsWe described two Chinese probands with genetically confirmed PORD and systematically reviewed published Chinese cases. Clinical features, POR genotypes, skeletal manifestations, adrenal function, DSD phenotypes, and reproductive features were extracted. Carrier frequency and modeled genetic prevalence were estimated using gnomAD and WBBC, with variants stratified by evidence of pathogenicity.
resultsThe pooled cohort included 40 unique Chinese patients, comprising two newly reported probands and 38 literature-derived cases. One proband carried p.R457H and a novel frameshift variant, p.N178Efs*28; the second carried p.R457H and p.Y607C. The recurrent p.R457H variant accounted for 40 of 80 alleles in the Chinese cohort. Using the expanded exploratory variant set, the modeled genetic prevalence was 2.4 per 1,000,000 individuals in WBBC Chinese and 3.3 per 1,000,000 individuals in gnomAD East Asians.
conclusionChinese patients with PORD show broad clinical heterogeneity, and p.R457H is a recurrent East Asian-enriched POR variant. The novel p.N178Efs*28 variant expands the POR mutational spectrum. Population-database estimates should be interpreted as modeled genetic prevalence rather than observed clinical incidence, especially when predicted deleterious variants are included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.